Infections and Infectious Diseases

  • Home
  • Infections and Infectious Diseases
Headache Relief Shampoo Voted #1 Best New Product in 2019

Dr. D’s Medicated Headache Relief Shampoo is now available. This medicated shampoo will help alleviate headaches simply by soaking it on your head. Finding relief from minor to severe headaches shouldn’t always involve reaching for a bottle of pills. Dr. D is here to give you another option. Our proprietary formula will leave your head feeling better.

BUY NOW! http://headachereliefshampoo.com/product/headache-relief-shampoo/

January 1, 2019 / by / in
Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men

Conditions:   Gonorrhea;   Chlamydia;   Syphilis
Intervention:   Drug: Doxycycline Hyclate Delayed-Release 200 mg
Sponsors:   University of California, San Francisco;   University of Washington;   National Institute of Allergy and Infectious Diseases (NIAID);   Mayne Pharma International Pty Ltd;   San Francisco Department of Public Health
Not yet recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 10, 2019 / by / in
A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants

Condition:   Respiratory Syncytial Virus Infections
Interventions:   Drug: MEDI8897;   Drug: Placebo
Sponsor:   MedImmune LLC
Not yet recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 8, 2019 / by / in
Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV

Conditions:   HIV Infection;   Opioid-use Disorder;   Cardiovascular Diseases
Interventions:   Drug: buprenorphine/naloxone;   Drug: Methadone;   Drug: Naltrexone Injection;   Drug: Heroin
Sponsors:   MetroHealth Medical Center;   National Institute on Drug Abuse (NIDA)
Recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 7, 2019 / by / in
A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ in Combination With Aztreonam

Condition:   Bacterial Infection
Interventions:   Drug: Aztreonam;   Drug: Ceftazidime-Avibactam
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 6, 2019 / by / in
Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection

Condition:   Recurrent Clostridium Difficile Infection
Interventions:   Drug: Penn Microbiome Therapy – 001;   Drug: Penn Microbiome Therapy – 002;   Drug: Penn Microbiome Therapy – 003
Sponsor:   University of Pennsylvania
Not yet recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 5, 2019 / by / in
NeuMoDx PrEDiCTiNG Study Evaluation Plan

Conditions:   Chlamydia Trachomatis Infection;   Neisseria Gonorrheae Infection
Interventions:   Diagnostic Test: NeuMoDx CT/NG Assay;   Diagnostic Test: FDA-cleared NAATs
Sponsors:   NeuMoDx Molecular, Inc.;   NAMSA
Not yet recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 3, 2019 / by / in
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Condition:   Multiple Sclerosis, Relapsing-Remitting
Interventions:   Drug: BIIB017 (peginterferon beta-1a);   Drug: Interferon beta type 1a
Sponsor:   Biogen
Recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 2, 2019 / by / in
A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals

Condition:   Healthy
Interventions:   Biological: Ad26.Mos4.HIV;   Biological: Clade C and Mosaic gp140 HIV bivalent vaccine;   Biological: Placebo
Sponsor:   Janssen Vaccines & Prevention B.V.
Not yet recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 1, 2019 / by / in